Trials / Completed
CompletedNCT02886598
Safety and Efficacy of Firmagon® (Degarelix) for Injection
Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Firmagon® (Degarelix) for Injection
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 368 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of Firmagon® (degarelix) for injection under the conditions of general clinical practice in Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | degarelix |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2019-03-26
- Completion
- 2019-03-26
- First posted
- 2016-09-01
- Last updated
- 2019-06-17
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02886598. Inclusion in this directory is not an endorsement.